Human Genome Sciences, Inc (HGSI)

[surf1944]

7:03AM Human Genome reported that it is entitled to fees and milestone payments that could amount to as much as $183 million from GlaxoSmithKline's (GSK) phase 3 trial for Albiglutide (HGSI) 8.09 : Albiglutide was created by HGSI using its proprietary albumin-fusion technology, and was licensed to GSK in 2004. HGSI is entitled to fees and milestone payments that could amount to as much as $183 mln-- including $33.0 mln received to date -- in addition to single-digit net royalties on worldwide sales if albiglutide is commercialized.